H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 34.6 DKK 0.44% Market Closed
Market Cap: 34.5B DKK

H Lundbeck A/S
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

H Lundbeck A/S
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
H Lundbeck A/S
CSE:HLUN A
Income from Continuing Operations
kr3.1B
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Income from Continuing Operations
kr103.8B
CAGR 3-Years
25%
CAGR 5-Years
20%
CAGR 10-Years
12%
ALK-Abello A/S
CSE:ALK B
Income from Continuing Operations
kr1.1B
CAGR 3-Years
49%
CAGR 5-Years
110%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Income from Continuing Operations
-kr34.5m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
34.3B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
57.34 DKK
Undervaluation 40%
Intrinsic Value
Price

See Also

What is H Lundbeck A/S's Income from Continuing Operations?
Income from Continuing Operations
3.1B DKK

Based on the financial report for Dec 31, 2024, H Lundbeck A/S's Income from Continuing Operations amounts to 3.1B DKK.

What is H Lundbeck A/S's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
34%

Over the last year, the Income from Continuing Operations growth was 37%. The average annual Income from Continuing Operations growth rates for H Lundbeck A/S have been 34% over the past three years .

Back to Top